Welcome to our dedicated page for Agilent Technologies news (Ticker: A), a resource for investors and traders seeking the latest updates and insights on Agilent Technologies stock.
Agilent Technologies Inc. reports developments across analytical and clinical laboratory technologies, including instruments, software, services and scientific expertise used by life science, diagnostics, applied, biopharmaceutical, chemical, advanced materials, clinical lab, environmental, food, forensics, academic and government customers. Company updates commonly address financial results, product launches, laboratory workflows and changes in senior legal, governance and compliance leadership.
Recent Agilent news has highlighted the BioTek Cytation 9 cell imaging multimode reader for cell-based research and high-content screening, cancer research and diagnostics workflows, and FDA-approved companion diagnostic indications for PD-L1 IHC 22C3 pharmDx, including use in identifying certain esophageal or gastroesophageal junction carcinoma patients who may be eligible for KEYTRUDA.
RTX A/S has announced new additions to its Sheerlink TM wireless solutions during the NAMM 'Believe in Music Week' event on January 20-21, 2022. These innovations allow manufacturers to double the number of active TX devices on one receiver while maintaining usability, latency, and audio quality at minimal additional costs. Enhanced features include an auxiliary audio channel for increased versatility and deployment using RTX1290 or RTX1090 modules, simplifying design processes amidst component supply challenges. RTX aims to expand product portfolios for customers through these advancements.
Agilent Technologies Inc. (NYSE: A) will announce its first-quarter fiscal year 2022 financial results on February 22, 2022, after market close. A live webcast of the investor conference call will take place the same day at 1:30 p.m. Pacific time. Agilent reported a revenue of $6.32 billion in fiscal 2021 and is recognized as a leader in life sciences and diagnostics, employing around 17,000 people globally. Access to the webcast will be available on Agilent's investor relations website for 90 days.
Summary not available.
Nicoya Lifesciences has secured a $20 million Series A extension led by Whitecap Venture Partners, with contributions from org value="NYSE:A"Agilent Technologies and others. This funding boosts the development of their Alto™ platform, which enhances protein characterization and aims to expand into new international markets. This extension increases Nicoya's total funding to $35 million, supporting over 500 researchers globally. Investors recognize the potential of Nicoya's innovative digital proteomics solutions in transforming life sciences.
Agilent Technologies Inc. (NYSE: A) will present at two major healthcare conferences: the Goldman Sachs 14th Annual Healthcare CEOs Unscripted Conference on January 6, 2022 at 11 a.m. ET and the J.P. Morgan 40th Annual Healthcare Conference on January 11, 2022 at 4:30 p.m. ET. Presentations will be made by CEO Mike McMullen and CFO Bob McMahon. Both events will be webcast, and further details can be found on Agilent's Investor Relations page. The company reported $6.32 billion in revenue for fiscal 2021.
Agilent Technologies Inc. (NYSE: A) has introduced compatibility of its Cary 3500 UV-Vis Spectrophotometer with the Agilent OpenLab software suite. This integration facilitates secure data management and compliance with global regulatory standards, addressing concerns highlighted in a recent survey about data integrity in pharma labs. The system enhances data security and improves efficiency by allowing simultaneous data collection and calibration in under five seconds. Agilent aims to support GMP labs in minimizing audit risks.
Agilent Technologies (NYSE: A) announced its participation in the Evercore ISI Virtual Healthcare Conference on December 1, 2021, at 11:20 a.m. ET. CEO Mike McMullen and CFO Bob McMahon will represent the company. The presentation will be available via webcast, with access links on Agilent's Investor Relations page. In fiscal 2021, Agilent generated $6.32 billion in revenue and employs around 17,000 employees globally.
Agilent Technologies reported a record-setting performance for fiscal year 2021, with fourth-quarter revenue of $1.66 billion, reflecting a 12% growth. The GAAP net income reached $442 million, resulting in an EPS of $1.45, a significant 104% increase year-over-year. For fiscal 2021, total revenue was $6.32 billion, an 18% increase, and full-year net income was $1.21 billion, with an EPS of $3.94.
Looking ahead, Agilent expects 2022 revenue between $6.65 billion and $6.73 billion, with first-quarter revenue guidance of $1.64 billion to $1.66 billion
Agilent Technologies (NYSE: A) has appointed Dr. Otis W. Brawley, a leading authority in oncology, to its board of directors, effective November 17, 2021. Dr. Brawley, who is affiliated with Johns Hopkins University, brings extensive expertise in cancer screening and prevention, focusing on reducing disparities in cancer care. His prior roles include chief medical and scientific officer at the American Cancer Society. Agilent's CEO, Mike McMullen, emphasized that Dr. Brawley's insights will enhance Agilent's cancer diagnostics focus, positioning the company as a leader in this area.
Agilent Technologies (NYSE: A) has announced an 8% increase in its quarterly dividend, raising it to 21 cents per share. This dividend will be payable on January 26, 2022, to shareholders on record as of January 4, 2022. The company reported $5.34 billion in revenue for fiscal year 2020 and employs approximately 16,400 people globally. Future dividends will be subject to board approval.